Achuta Guddati, MD
Hematology & Oncology · Stony Brook, NYNPI 1457639312
Payments from drug & device makers
Across 103 payments — averaging $2032.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$208K
- Daiichi Sankyo Inc.$1K
- Caris MPI, Inc.$132
- Sanofi$125
- AstraZeneca$33
- E.r. Squibb & Sons, L.L.C.$28
- plus $53 from 3 others
What the payments were for
- Consulting fees$1,17546%
- Speaking & faculty fees$1255%
- Travel & lodging$72829%
- Food & beverage$52421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 94 | $207,823 |
| Daiichi Sankyo Inc. | 2 | $1,175 |
| Caris MPI, Inc. | 1 | $132 |
| Sanofi | 1 | $125 |
| AstraZeneca | 1 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Bayer | 1 | $21 |
| Epizyme, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$764
- VANFLYTa$650
- Enhertu$525
- MI CANCER SEEK$132
- CAPRELSA$125
How this compares
$209,369 in reported general payments places this provider in the 75th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 12 | $186,047 |
| EliquisApixaban | 22 | $14,485 |
| Ondansetron Hcl | 24 | $1,356 |
| Prochlorperazine Maleate | 30 | $595 |
| Oxycodone Hcl | 14 | $267 |
| Ondansetron OdtOndansetron | 12 | $177 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Stony Brook
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Yelena JanjigianNew York$16.9M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Richard ZunigaBabylon$10.9M
- Scott TagawaNew York$10.3M
- Mohammad Abdul HayNew York$9.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.